Zhifei Biological shareholders approve key governance and management changes

Chongqing Zhifei Biological Products Co. Ltd. held its second extraordinary general meeting of shareholders in 2025 on November 18, 2025. A total of 743 shareholders, representing 1,350,986,313 shares, participated through a combination of on-site and online voting. The meeting, chaired by Jiang Rensheng, saw the approval of all resolutions.

Key resolutions included the revision of the company's articles of association and its attachments, which passed with 98.2843% of votes in favor. The "Investment and Financing and Guarantee Management System" was approved by 98.2682% of votes, while the "Connected Transaction Decision-making System" received 98.2756% approval.

Further governance updates included the "Management System for Raised Funds" with 98.2694% approval, the "Independent Director Work System" with 98.2621% approval, and the "Compensation Management System for Directors and Senior Management Personnel" with 99.8376% of votes in favor. Beijing King & Wood Mallesons (Chongqing) LLP provided a legal opinion confirming the legality and validity of the meeting's procedures and resolutions.